AI辅助炒股哪家强

Medipost Reports Positive Phase 3 Results for CARTISTEM in Japan’s Knee Osteoarthritis Trial_蜘蛛资讯网

clear statistical significance across all primary and secondary efficacy endpoints in the Japanese Phase 3 trial.Lee added that the Japanese Phase 3 results reaffirm CARTISTEM's exceptional efficacy a

tablished in Korean Phase 3 trials, solidifies its potential as a disease-modifying osteoarthritis drug (DMOAD). This positions CARTISTEM strongly for entry into the global market as a treatment that

当前文章：http://dlao7kv.wenxuanke.cn/ulei52/onpi7.html

发布时间：00:00:00